Daniel P. Hollern

3.4k total citations · 1 hit paper
27 papers, 1.3k citations indexed

About

Daniel P. Hollern is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Daniel P. Hollern has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Daniel P. Hollern's work include Cancer-related Molecular Pathways (8 papers), Cancer Cells and Metastasis (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Daniel P. Hollern is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Cancer Cells and Metastasis (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Daniel P. Hollern collaborates with scholars based in United States, China and Spain. Daniel P. Hollern's co-authors include Eran R. Andrechek, Mara Gilardi, Brad H. Nelson, Céline M. Laumont, Allyson C. Banville, Jiayu Liao, Xianju Zhou, Charles M. Perou, Robert D. Cardiff and Kevin R. Mott and has published in prestigious journals such as Cell, Nature reviews. Cancer and Molecular and Cellular Biology.

In The Last Decade

Daniel P. Hollern

26 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities

2022 304 citations Céline M. Laumont, Allyson C. Banville et al. Nature reviews. Cancer profile →

Peers

Daniel P. Hollern

ONCOL

IMMUN

PRM

Anne Krogsdam Austria

Susana García‐Recio Spain

Shari L. Sutor United States

Paulien Cornelissen‐Steijger Netherlands

Elise T. Courtois United States

Veena Padmanaban United States

Dong Hua China

Harihar Basnet United States

Yasuharu Akasaki Japan

Geoffrey J. Markowitz United States

Anne Krogsdam Austria

Daniel P. Hollern

480 ×0.7

ONCOL

630 ×1.1

394 ×1.0

IMMUN

215 ×0.8

138 ×0.7

PRM

Citations per year, relative to Daniel P. Hollern Daniel P. Hollern (= 1×) peers Anne Krogsdam

Countries citing papers authored by Daniel P. Hollern

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Hollern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Hollern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Hollern more than expected).

Fields of papers citing papers by Daniel P. Hollern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Hollern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Hollern. The network helps show where Daniel P. Hollern may publish in the future.

Co-authorship network of co-authors of Daniel P. Hollern

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Hollern. A scholar is included among the top collaborators of Daniel P. Hollern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Hollern. Daniel P. Hollern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mukherjee, Angana, Aaron Ebbs, Daniel P. Hollern, et al.. (2024). DAB2IP loss in luminal a breast cancer leads to NF-κB–associated aggressive oncogenic phenotypes. JCI Insight. 9(23). 1 indexed citations

Hollern, Daniel P.. (2024). Memory B cell fitness and anergy has significant links to cancer lethality. Cell. 187(17). 4551–4553. 2 indexed citations

Rempel, Rachel E., Jonathan Rennhack, Daniel P. Hollern, et al.. (2024). Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model. Oncogene. 43(46). 3402–3415.

Lui, Asona, et al.. (2023). The Evolving Landscape of B Cells in Cancer Metastasis. Cancer Research. 83(23). 3835–3845. 7 indexed citations

Gilardi, Mara, Robert Saddawi‐Konefka, Victoria H. Wu, et al.. (2022). Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs. Molecular Cancer Therapeutics. 21(4). 616–624. 34 indexed citations

Rennhack, Jonathan, et al.. (2022). Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH. PLoS Genetics. 18(9). e1010362–e1010362. 6 indexed citations

Bai, Feng, Chuying Wang, Xiong Liu, et al.. (2022). Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway. Cell Death and Disease. 13(3). 195–195. 14 indexed citations

Laumont, Céline M., Allyson C. Banville, Mara Gilardi, Daniel P. Hollern, & Brad H. Nelson. (2022). Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nature reviews. Cancer. 22(7). 414–430. 304 indexed citations breakdown →

Garay, Joseph P., Rebecca Smith, Kaylyn L. Devlin, et al.. (2021). Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Breast Cancer Research. 23(1). 81–81. 8 indexed citations

10.

Bai, Feng, Shiqin Liu, Xiong Liu, et al.. (2021). PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors. Breast Cancer Research. 23(1). 10–10. 19 indexed citations

11.

Williams, Mark V., Xinhui Liu, Yueqi Zhang, et al.. (2020). NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin. Oncogene. 39(19). 3821–3836. 19 indexed citations

12.

Selitsky, Sara R., David Marron, Daniel P. Hollern, et al.. (2020). Virus expression detection reveals RNA-sequencing contamination in TCGA. BMC Genomics. 21(1). 79–79. 20 indexed citations

13.

Hollern, Daniel P., Nuo Xu, Aatish Thennavan, et al.. (2019). B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 179(5). 1191–1206.e21. 307 indexed citations

14.

Tanioka, Maki, Kevin R. Mott, Daniel P. Hollern, et al.. (2018). Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Medicine. 10(1). 86–86. 14 indexed citations

15.

Broin, Pilib Ó, Daniel P. Hollern, Silvia E. Racedo, et al.. (2016). LPA receptor activity is basal specific and coincident with early pregnancy and involution during mammary gland postnatal development. Scientific Reports. 6(1). 35810–35810. 8 indexed citations

16.

Chen, Fengsheng, Shenglan Gao, Daniel P. Hollern, et al.. (2014). Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression. Cell Death and Disease. 5(5). e1242–e1242. 2 indexed citations

17.

Hollern, Daniel P., et al.. (2014). Abstract 988: A mouse model gene expression database reveals E2Fs as key regulators of breast cancer metastasis. Cancer Research. 74(19_Supplement). 988–988. 1 indexed citations

18.

Zhou, Xianju, et al.. (2013). NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death and Disease. 4(3). e560–e560. 158 indexed citations

19.

Hollern, Daniel P., et al.. (2012). A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer. Oncogene. 32(10). 1296–1304. 19 indexed citations

20.

Fujiwara, Kenichiro, et al.. (2011). Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc-Induced Tumors. Cancer Research. 71(5). 1924–1932. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact